AgPlenus to Present at the 14th International IUPAC 2019 Conference
Boaz Inbal, VP R&D, will present AgPlenus' unique computational approach
Rehovot, Israel – May 15, 2019 - AgPlenus, a fully owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), an innovative company aiming to design effective and sustainable crop protection products by leveraging predictive biology, announces today that it will participate in the 14th International IUPAC conference on Crop Protection which will be a conjoined event with the European Crop Protection Association (ECPA) and the International Symposium of Crop Protection (ISCP). The conference will and take place in Ghent, Belgium, at the International Convention Centre (ICC) on May 19-24, 2019.
Dr. Boaz Inbal, AgPlenus’ VP R&D, will present AgPlenus’ computational predictive approach for herbicide discovery & optimization, with a specific focus on resistance, which is a critical challenge in the Ag-industry today.
The 14th International IUPAC conference on Crop Protection that will take place in Ghent, Belgium, at the International Convention Centre (ICC) on May 19-24, 2019, Dr. Inbal will give two presentations:
“A computational predictive approach to address target specific resistance to pesticides” , scheduled to take place on Tuesday, May 21, at 15:50.
“A computational predictive approach for the discovery and optimization of new crop protection compounds”, scheduled to take place on Friday, May 24, at 11:40.
About AgPlenus Ltd.:
AgPlenus is designing effective and sustainable crop protection products by leveraging predictive biology. The Company aims to develop crop protection products: herbicides, insecticides, fungicides and crop enhancers. AgPlenus will continue ongoing collaborations with industry leaders such as BASF and ICL. AgPlenus is a fully owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN). For more information, please visit www.agplenus.com
About Evogene Ltd.:
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and cutting-edge computational technologies. Today, this platform is utilized by the Company and its subsidiaries to discover and develop innovative products in the following areas: ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions and human microbiome-based therapeutics. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in its collaborations with world-leading companies such as BASF, Corteva, Bayer and ICL. For more information, please visit www.evogene.com
Forward Looking Statements:
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’s control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.